Mayne Pharma Group Limited
MAYNF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $416 | $370 | $317 | $19 |
| - Cash | $60 | $110 | $102 | $97 |
| + Debt | $41 | $70 | $48 | $414 |
| Enterprise Value | $398 | $331 | $263 | $336 |
| Revenue | $408 | $388 | $184 | $157 |
| % Growth | 5.1% | 111.4% | 16.8% | – |
| Gross Profit | $247 | $219 | $27 | $170 |
| % Margin | 60.6% | 56.3% | 14.6% | 108.3% |
| EBITDA | $42 | -$87 | -$174 | -$46 |
| % Margin | 10.3% | -22.4% | -95% | -29.5% |
| Net Income | -$94 | -$174 | $117 | -$209 |
| % Margin | -23% | -44.9% | 63.9% | -133.3% |
| EPS Diluted | -1.14 | -2.12 | -3.67 | -3.2 |
| % Growth | 46.2% | 42.2% | -14.7% | – |
| Operating Cash Flow | $17 | -$15 | -$43 | -$17 |
| Capital Expenditures | -$12 | -$21 | -$220 | -$12 |
| Free Cash Flow | $5 | -$36 | -$263 | -$28 |